Long term follow-up of EGFR mutated NSCLC cases

Gad Rennert*, Maya Gottfried, Hedy S. Rennert, Flavio Lejbkowicz, Meira Frank, Ilana Cohen, Shiri Kelt, Abed Agbarya, Elizabeta Dudnik, Julia Dudnik, Rivka Katznelson, Moshe Mishali, Natalie Maimon Rabinovich, Hovav Nechushtan, Amir Onn, Shoshana Keren Rosenberg, Mariana Wollner, Alona Zer, Jair Bar, Naomi Gronich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: A substantial fraction of all non-small cell lung cancers(NSCLC) carry a mutation in the EGFR gene for which an effective treatment with anti-tyrosine kinases(TKIs) is available. We studied the long term survival of these patients following the introduction of TKIs. Experimental design: All consecutive cases of NSCLC newly diagnosed with advanced disease were referred for free tumor EGFR mutation testing at Clalit's national personalized medicine laboratory. Mutations and deletions in target codons 18–21 of EGFR were sought using RT-PCR and fragment analysis. Comprehensive EMRs were used to collect full data on treatments and clinical status. Results: A cohort of 3,062 advanced NSCLC cases, included 481(15.7%) somatic EGFR mutation carriers (17.5% of all adenocarcinomas, 26.7% of females with adenocarcinomas). TKIs treatment to EGFR mutation carriers was provided to 85% of all eligible. After a median follow up period of 15.9 months for EGFR mutated cases the hazard ratio for overall survival of EGFR-mutated NSCLC treated with TKIs was 0.55(0.49–0.63, p<0.0001) when compared with EGFR wild-type(WT) tumors under usual care. After adjusting for age, sex, ethnicity, smoking history and tumor histology, all of which had an independently significant effect on survival, the HR for TKI-treated, EGFR-mutated tumors, was 0.63 (0.55–0.71, p<0.0001). Treating EGFR-WT cases with TKIs yielded a high HR=1.32 (1.19–1.48). Conclusions: TKIs given to EGFR mutated advanced NSCLC demonstrated a substantial survival benefit for at least five years. Squamous histology, smoking, male sex and Arab ethnicity were associated with higher NSCLC mortality hazard. Treating non-EGFR-mutated NSCLC with TKIs seems detrimental. Statement of Significance: • TKIs given to EGFR mutated advanced NSCLC demonstrated a substantial survival benefit for at least five years but not much longer. • Treating non-EGFR-mutated NSCLC with TKIs seems detrimental and should probably be avoided. • Squamous histology of non-small cell lung cancer, smoking history, male sex and Arab ethnicity were associated with altogether higher NSCLC mortality hazard.

Original languageEnglish
Article number100934
JournalTranslational Oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Long term follow-up of EGFR mutated NSCLC cases'. Together they form a unique fingerprint.

Cite this